Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model

The widely used chemotherapy cisplatin causes permanent hearing loss in 40%–60% of patients with cancer. One drug, sodium thiosulfate, is approved by the FDA for use in pediatric patients with localized solid tumors for preventing cisplatin-induced hearing loss, but more drugs are desperately needed...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Matthew A. Ingersoll, Richard D. Lutze, Chithra K. Pushpan, Regina G. Kelmann, Huizhan Liu, Mark T. May, William J. Hunter, David Z.Z. He, Tal Teitz
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	American Society for Clinical investigation 2023-12-01
Serie:	JCI Insight
Soggetti:	Otology Therapeutics
Accesso online:	https://doi.org/10.1172/jci.insight.171140
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!